AU2021313124A1 - Method for treating graft versus host disease caused by hematopoietic stem cell transplantation - Google Patents
Method for treating graft versus host disease caused by hematopoietic stem cell transplantation Download PDFInfo
- Publication number
- AU2021313124A1 AU2021313124A1 AU2021313124A AU2021313124A AU2021313124A1 AU 2021313124 A1 AU2021313124 A1 AU 2021313124A1 AU 2021313124 A AU2021313124 A AU 2021313124A AU 2021313124 A AU2021313124 A AU 2021313124A AU 2021313124 A1 AU2021313124 A1 AU 2021313124A1
- Authority
- AU
- Australia
- Prior art keywords
- days
- compound
- group
- administered
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010713637 | 2020-07-22 | ||
| CN202010713637.0 | 2020-07-22 | ||
| PCT/CN2021/107575 WO2022017412A1 (zh) | 2020-07-22 | 2021-07-21 | 治疗造血干细胞移植后的移植物抗宿主病的方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021313124A1 true AU2021313124A1 (en) | 2023-03-09 |
Family
ID=79728482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021313124A Pending AU2021313124A1 (en) | 2020-07-22 | 2021-07-21 | Method for treating graft versus host disease caused by hematopoietic stem cell transplantation |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230285393A1 (https=) |
| EP (1) | EP4186508A4 (https=) |
| JP (1) | JP7803924B2 (https=) |
| KR (1) | KR20230043891A (https=) |
| CN (2) | CN121846099A (https=) |
| AU (1) | AU2021313124A1 (https=) |
| BR (1) | BR112023001049A2 (https=) |
| CA (1) | CA3186564A1 (https=) |
| IL (1) | IL299985A (https=) |
| TW (2) | TW202216691A (https=) |
| WO (1) | WO2022017412A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL311447A (en) * | 2021-09-18 | 2024-05-01 | Beijing Tide Pharmaceutical Co Ltd | A solid form of a Rho-linked protein kinase inhibitor or a solvate thereof, a method of preparation and use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120202793A1 (en) * | 2009-03-09 | 2012-08-09 | Paul Sweetnam | Rho kinase inhibitors |
| CN113620933A (zh) * | 2012-10-05 | 2021-11-09 | 卡德门企业有限公司 | Rho激酶抑制剂 |
| WO2018039539A1 (en) * | 2016-08-26 | 2018-03-01 | Lycera Corporation | Indazolyl-l,2,4-thiadiazolamines and related compounds for inhibition of rho-associated protein kinase and the treatment of disease |
| CN110582489B (zh) | 2017-06-30 | 2023-10-27 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 |
| WO2019000682A1 (zh) * | 2017-06-30 | 2019-01-03 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 |
| US10323023B2 (en) * | 2017-06-30 | 2019-06-18 | Beijing Tide Pharmaceutical Co., Ltd. | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof |
| TWI818919B (zh) * | 2017-08-15 | 2023-10-21 | 美商歐米諾斯公司 | 用於治療和／ 或預防與造血幹細胞移植有關的移植物抗宿主病和／ 或瀰漫性肺泡出血和／ 或靜脈閉塞性病的方法 |
-
2021
- 2021-07-21 AU AU2021313124A patent/AU2021313124A1/en active Pending
- 2021-07-21 CN CN202610271426.3A patent/CN121846099A/zh active Pending
- 2021-07-21 CA CA3186564A patent/CA3186564A1/en active Pending
- 2021-07-21 TW TW110126814A patent/TW202216691A/zh unknown
- 2021-07-21 BR BR112023001049A patent/BR112023001049A2/pt unknown
- 2021-07-21 EP EP21845732.3A patent/EP4186508A4/en active Pending
- 2021-07-21 IL IL299985A patent/IL299985A/en unknown
- 2021-07-21 JP JP2023504356A patent/JP7803924B2/ja active Active
- 2021-07-21 WO PCT/CN2021/107575 patent/WO2022017412A1/zh not_active Ceased
- 2021-07-21 US US18/017,198 patent/US20230285393A1/en active Pending
- 2021-07-21 TW TW112113471A patent/TWI868660B/zh active
- 2021-07-21 CN CN202180059344.8A patent/CN116322670A/zh active Pending
- 2021-07-21 KR KR1020237005450A patent/KR20230043891A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023535035A (ja) | 2023-08-15 |
| EP4186508A1 (en) | 2023-05-31 |
| TW202216691A (zh) | 2022-05-01 |
| IL299985A (en) | 2023-03-01 |
| KR20230043891A (ko) | 2023-03-31 |
| CN116322670A (zh) | 2023-06-23 |
| WO2022017412A1 (zh) | 2022-01-27 |
| CN121846099A (zh) | 2026-04-14 |
| TWI868660B (zh) | 2025-01-01 |
| EP4186508A4 (en) | 2024-10-16 |
| US20230285393A1 (en) | 2023-09-14 |
| JP7803924B2 (ja) | 2026-01-21 |
| TW202327609A (zh) | 2023-07-16 |
| CA3186564A1 (en) | 2022-01-27 |
| BR112023001049A2 (pt) | 2023-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12582653B2 (en) | Method for treating idiopathic pulmonary fibrosis | |
| AU2020230574B2 (en) | Method for treating fatty liver disease and/or steatohepatitis | |
| WO2021248079A1 (en) | Heterocyclic compounds and methods of use thereof | |
| JP2024519098A (ja) | スピロ系化合物およびその使用 | |
| WO2021248095A1 (en) | Heterocyclic compounds and methods of use thereof | |
| US11292799B2 (en) | Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | |
| KR20140095105A (ko) | 대장염 치료용 조성물 및 방법 | |
| CN114375193A (zh) | 甲状腺激素受体β激动剂化合物 | |
| AU2021313124A1 (en) | Method for treating graft versus host disease caused by hematopoietic stem cell transplantation | |
| HK40086216A (en) | Method for treating graft versus host disease caused by hematopoietic stem cell transplantation | |
| EP3960179B1 (en) | Method for treating cough by using diaminopyrimidine compound | |
| CA3138780C (en) | Method for treating cough by using diaminopyrimidine compound | |
| HK40062124A (en) | Method for treating cough by using diaminopyrimidine compound | |
| HK40064686A (en) | Method for treating idiopathic pulmonary fibrosis | |
| US20230212174A1 (en) | Pyrrolo[2,1-f][1,2,4]triazine derivative and use thereof | |
| KR20250139885A (ko) | G 단백질 결합된 수용체 키나아제 2(grk2) 분해 화합물 및 이의 용도 | |
| HK40063168A (en) | Method for treating cough by using diaminopyrimidine compound | |
| HK40063173A (en) | Method for treating idiopathic pulmonary fibrosis | |
| HK40058942A (en) | Method for treating fatty liver disease and/or steatohepatitis | |
| WO2020139701A1 (en) | Compounds, compositions, and methods for modulating androgen receptor activity |